Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy
Public ClinicalTrials.gov record NCT00632385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Study of Eletriptan for the Acute Treatment of Migraine in Migraine Sufferers Who Are Dissatisfied With Rizatriptan Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy
Study identification
- NCT ID
- NCT00632385
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 127 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2003 (Type not available)
- Primary completion
- Not listed
- Completion
- Aug 2003 (Actual)
- Last update posted
- Jan 27, 2021
2003
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Irvine | California | 92618 | — |
| Pfizer Investigational Site | Newport Beach | California | 92660-2452 | — |
| Pfizer Investigational Site | San Francisco | California | 94109 | — |
| Pfizer Investigational Site | Plantation | Florida | 33324 | — |
| Pfizer Investigational Site | St. Petersburg | Florida | 33710 | — |
| Pfizer Investigational Site | Tampa | Florida | 33609 | — |
| Pfizer Investigational Site | Marietta | Georgia | 30067 | — |
| Pfizer Investigational Site | South Bend | Indiana | 46601 | — |
| Pfizer Investigational Site | Milford | Massachusetts | 01757 | — |
| Pfizer Investigational Site | Chesterfield | Missouri | 63017 | — |
| Pfizer Investigational Site | Springfield | Missouri | 65804 | — |
| Pfizer Investigational Site | Greensboro | North Carolina | 27403 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45219 | — |
| Pfizer Investigational Site | Eugene | Oregon | 97401 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Alexandria | Virginia | 22304 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00632385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 27, 2021 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00632385 live on ClinicalTrials.gov.